Erschienen in:
08.02.2023 | Nutrition and Obesity (C Newberry, Section Editor)
Obesity Pharmacotherapy: a Review of Current Practices and Future Directions
verfasst von:
Sarah Schmitz, MD, Beverly G. Tchang, MD, Alpana P. Shukla, MD MRCP (UK)
Erschienen in:
Current Treatment Options in Gastroenterology
|
Ausgabe 1/2023
Einloggen, um Zugang zu erhalten
Abstract
Purpose of Review
The aim of this article is to review the current pharmacologic treatment options available for the treatment of obesity. The efficacy of each medication and its effect on cardiometabolic profile is highlighted. The use of off-label medications is discussed, along with medications currently under development.
Recent Findings
Achieving and maintaining long-term clinically significant weight loss is likely to require the use of two or more anti-obesity medications. While the current evidence for combination therapies is limited, polypharmacotherapy is an area of active research, and emerging therapies are anticipated to be multi-target agents. Promising medications in the pipeline include dual GLP-1/GIP receptor agonists, combination GLP-1 receptor agonists and amylin analogues, dual GLP-1/glucagon receptor agonists, and tripeptides.
Summary
This review aims to summarize the current pharmacologic treatment options available for the treatment of obesity. Medication regimens should be individualized to the patient to optimize benefits versus risks. Consider combinations of anti-obesity medications with different mechanisms to overcome the biological compensatory mechanisms that drive weight regain. Off-label prescribing may be necessary to overcome barriers to care and should be informed by current evidence.